Highlights from the ATS 2020 Virtual Congress – Slide kit

Nuove analisi su IPF, PF-ILD e SSc-ILD presentate al Congresso Internazionale ATS 2020

Nel seguente slike kit sono riportate le principali analisi in ambito ILD presentate al Congresso Internazionale ATS 2020:

IPF

• Effects of nintedanib in subgroups based on combined pulmonary fibrosis and emphysema (CPFE) index at baseline (Cottin V, et al.)

• Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and multiple comorbidities (Glaspole I, et al.)

• Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis: subgroup analyses by TORVAN stage (Torrisi S, et al.)

PF-ILD

• Effect of nintedanib on FVC decline in patients with progressive fibrosing ILDs (Cottin V, et al.)

• Effects of nintedanib on dyspnea, cough and quality of life in patients with progressive fibrosing interstitial lung diseases (ILDs) (Swigris JJ et al.)

SSc-IL

• Lung function decline in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) by time since first non-Raynaud symptom (Distler O, et al.)

• Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) by body mass index (BMI) at baseline (Jouneau S, et al.)

• Effect of nintedanib on progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD) beyond 52 weeks (Maher TM, et al.)